Novoheart

🚀 Advancing Cardiac Drug Screening with Machine Learning and Engineered Mini-Hearts! 🫀 Novoheart is revolutionizing drug discovery with our innovative human mini-heart drug screening platform. By leveraging human stem cell-derived tissue assays, we’re able to replicate the human heart’s complex biology and function in the lab: Cardiac Anisotropic Sheet (hvCAS) for electrophysiology Cardiac Tissue Strip (hvCTS) for contractility Cardiac Organoid Chamber (hvCOC), aka Human Heart-in-a-Jar, for pump function Integrating these assays with advanced machine learning (ML), we’ve achieved an impressive 86.2% predictive accuracy in classifying drug mechanisms—setting a new standard in cardiac drug testing and surpassing previous ML methods.   This milestone aligns with the FDA Modernization Act 2.0, championing alternatives to animal testing and accelerating the development of safer, more effective therapies for patients. We are proud to be part of the future of cardiac research and pharma innovation. 🔬 Together, we can make a lasting impact on global heart health. 🌍 #CardiacResearch #PharmaInnovation #FDA #MachineLearning #HeartHealth #DrugDiscovery #Biotech #CardiovascularResearch

Contractile performance is an essential function of the human heart. 2-D cardiomyocyte cultures are inadequate for assessing contractility as they cannot perform physiological contractions on rigid plasticware. Novoheart’s human ventricular Cardiac Tissue Strip (hvCTS) offers a superior contractility assay. This assay consists of aligned hvCM in a 3-D hydrogel mixture that is constructed using a custom-designed cartridge with integrated force-sensing posts at the ends. This model has been validated as a sensitive and reliable predictor of clinical drug responses or pathologic effects on cardiac contractility.  The CTScreen is Novoheart’s all-in-one screening system for comprehensive cardiac tissue contractility studies. Our unique system enables programmable force measurement protocols, including automated perfusion, electrical stimulation, data acquisition and streamlined data analysis. Customizable cartridges have been designed for the CTScreen to allow multiple tissues to be fabricated and cultured on each cartridge at the same time. All cartridges are compatible with Novoheart’s commercial CTScreen platform. #CTScreen #drugdiscovery #drugscreening #cardiac #3dcellculture #biotech #bioengineering

In early May, Novoheart had the opportunity to demo Miltenyi Biotec's UltraMicroscope Blaze – the light sheet microscope’s lightspeed mode allowed us to image multiple markers on entire engineered cardiac tissues in minutes. What an incredible tool for efficiently understanding both live and fixed tissue composition and structure. Thank you to Simon Merz, PhD and Rachel Roccanova, Ph.D., and the rest of the Miltenyi team who came onsite and made this such a valuable experience!

Medera's CEO, Prof Ronald Li, and Sardocor's President, Prof Roger Hajjar were panel members at the CRIS discussion on Opportunities and Challenges in Investing in Cardiovascular and Cancer, Cell and Gene Therapy. #cardiovascular #cellandgenetherapy #heartdisease

Novoheart is excited to share that their bioengineered HFpEF Human mini-Heart models played a crucial role in Sardocor's ability to obtain Fast Track Designation for their investigational gene therapy treatment for HFpEF. Sardocor's clinical-grade AAV vector, SRD-001, was tested on both human ventricular Cardiac Tissue Strips #hvCTS and #hvCOC at Novoheart. Read the full press release here. https://lnkd.in/eeFzMbdD #heart #heartfailure #disease modeling

Contractile performance is an essential function of the human heart. 2-D cardiomyocyte cultures are inadequate for assessing contractility as they cannot perform physiological contractions on rigid plasticware. Novoheart’s human ventricular Cardiac Tissue Strip (hvCTS) offers a superior contractility assay. This assay consists of aligned hvCM in a 3-D hydrogel mixture that is constructed using a custom-designed cartridge with integrated force-sensing posts at the ends. This model has been validated as a sensitive and reliable predictor of clinical drug responses or pathologic effects on cardiac contractility.  The CTScreen is Novoheart’s all-in-one screening system for comprehensive cardiac tissue contractility studies. Our unique system enables programmable force measurement protocols, including automated perfusion, electrical stimulation, data acquisition and streamlined data analysis. Customizable cartridges have been designed for the CTScreen to allow multiple tissues to be fabricated and cultured on each cartridge at the same time. All cartridges are compatible with Novoheart’s commercial CTScreen platform. #CTScreen #drugdiscovery #drugscreening #cardiac #3dcellculture #biotech #bioengineering

With the world’s first mini-Heart technology platform, Novoheart has previously partnered with AstraZeneca to construct the first HFpEF mini-Heart by molecular induction. The results have led to an ongoing FDA-approved First-In-Human Gene Therapy clinical trial in the United States. We proudly announce that Novoheart partners with National Heart Centre Singapore (NHCS) to create the world’s first Asian patient-specific miniature human heart model with heart failure, known as “Human Heart-in-a-Jar.” #Medera Inc #iPSC #mini-Heart #Novoheart #NHCS https://lnkd.in/g97Y-pdX